personalized medicine
Medicare Covering BillionToOne Northstar Select Cancer Liquid Biopsy Test
The company's tumor genotyping test will now be reimbursed for eligible Medicare patients under Palmetto GBA's local coverage determination for this class of assays.
Pillar Biosciences Receives CMS Coverage for Pan-Cancer CDx Assay
The firm's next-generation sequencing-based test detects single nucleotide variants, insertions, and deletions in 22 genes.
A discussion at the Precision Medicine Tri-Con demonstrated that stakeholders are narrowing in on the challenges to realizing the promise of solid tumor MRD.
Real-World Data Analysis Confirms Pan-Cancer Predictiveness of Foundation Medicine TMB Caller
Premium
The company worked with clinical investigators to analyze outcomes data across more than 8,000 treated individuals, reconfirming the validity of its FDA-approved TMB indication.
New York State DOH Approves Solvd Lab for Clinical PGx Testing
The company markets an assay intended to predict patients' risk of developing opioid use disorder, helping physicians tailor their use of these drugs.